Targeted Oncology2 小时
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
MediciNova (NASDAQ:MNOV) Stock Passes Above 200 Day Moving Average – Here’s Why
MediciNova, Inc. (NASDAQ:MNOV – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.69 and traded as high ...